Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224336 · ClinicalTrials.gov registry record · Phase 1
Psilocybin-assisted Therapy for Phantom Limb Pain
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05224336 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 10 participants.
The verdict
NCT05224336, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This double-blind placebo-controlled pilot study seeks to investigate whether psilocybin can be safely administered to people with chronic phantom limb pain (PLP) in a supportive setting with close follow-up, and its effects on pain symptoms and other moods, attitudes, and behaviors. The investigators' primary hypotheses are that psilocybin is safe to administer in people with PLP and that it will reduce scores on measures of pain. The investigators will also assess a number of secondary measures related to the behavioral and neural responses to pain after psilocybin treatment.
Interventions
- DRUG Psilocybin
- DRUG Placebo Niacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05224336
The ClinicalTrials.gov registry entry for NCT05224336 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Psilocybin is the first listed.
NCT05224336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05224336 about?
NCT05224336 is a clinical study titled "Psilocybin-assisted Therapy for Phantom Limb Pain". This double-blind placebo-controlled pilot study seeks to investigate whether psilocybin can be safely administered to people with chronic phantom limb pain (PLP) in a supportive setting with close follow-up, and its effects on pain symptoms and other moods, attitudes, and behaviors. The investigato...
What is the current status of trial NCT05224336?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-10-03. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT05224336?
The interventions under investigation include: Psilocybin (DRUG), Placebo Niacin (DRUG).
Who is sponsoring clinical trial NCT05224336?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.